News (ZH) - LGC Clinical Diagnostics, a leader in quality solutions for molecular diagnostics, is delighted to announce the launch of the Seraseq® DPYD DNA Mutation Mix. This launch marks LGC Clinical Diagnostics’ entry into the rapidly expanding field of pharmacogenomics, furthering its commitment to personalized medicine. This cutting-edge reference material is designed for developing, validating, and routinely evaluating Next Generation Sequencing (NGS) assays and other molecular assays that detect critical mutations in the DPYD gene.
News (ZH) - Melbourne, 19 September 2024 -- Illumina (NASDAQ: ILMN) a global leader in genomics, and LGC Biosearch Technologies™, a pioneer in agricultural genomics, today announced a strategic partnership to accelerate the adoption of genomics in agricultural applications.
News (ZH) - LGC appoints Dr Alexander Zahiri as Executive Vice President & General Manager, Axolabs
News (ZH) - LGC appoints Marcus Kaeller as Chief Financial Officer
News (ZH) - Pioneering Cancer Treatments through Enhanced Genomic Profiling in the GenomeMET Project
News (ZH) - The National Measurement Laboratory and UK NEQAS for Leucocyte Immunophenotyping announce collaboration to improve quality assessment schemes for Chronic Myeloid Leukaemia Minimal Residual Disease testing
News (ZH) - LGC Biosearch Technologies™ launches a groundbreaking nucleic acid extraction method, sbeadex™ Lightning. This groundbreaking product rapidly delivers high-purity DNA in high-yields, typically achieving results in 5 minutes